QNRX QUOIN PHARMACEUTICALS LTD

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 13, 2025.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: .

For further information, contact:

Quoin Pharmaceuticals Ltd.

Michael Myers, Ph.D., CEO

Investor Relations

PCG Advisory

Jeff Ramson 



(646) 863-6341



EN
06/05/2025

Underlying

QNRXQUOIN PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUOIN PHARMACEUTICALS LTD

 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX...

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index (CDLQI) all demonstrated improvement from baseline QRX003 is being well tolerated and no adverse events have been reportedPatient is expected to continue to be treated with QRX003 to assess progressCompany continues to advance ...

16h 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Provides Corporate Update and Announces First Qu...

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline GrowthLaunch of NETHERTON NOW Advocacy Initiative ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage, specialty pharmaceutical company focused on develop...

May 13, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results...

Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 13, 2025. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and fina...

May 6, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price...

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement under Nas...

April 30, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Releases Second Episode of its “Living with Neth...

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on the development a...

April 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch